Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1-Reference-Cited by-同舟云学术

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

Published:2022-02-28 Issue:3 Volume:28 Page:545-556
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

McCulloch John A.,Davar Diwakar,Rodrigues Richard R.,Badger Jonathan H.^ORCID,Fang Jennifer R.^ORCID,Cole Alicia M.^ORCID,Balaji Ascharya K.,Vetizou Marie,Prescott Stephanie M.^ORCID,Fernandes Miriam R.,Costa Raquel G. F.,Yuan Wuxing,Salcedo Rosalba,Bahadiroglu Erol,Roy Soumen,DeBlasio Richelle N.,Morrison Robert M.^ORCID,Chauvin Joe-Marc,Ding Quanquan,Zidi Bochra,Lowin Ava,Chakka Saranya,Gao Wentao,Pagliano Ornella,Ernst Scarlett J.,Rose Amy,Newman Nolan K.,Morgun Andrey,Zarour Hassane M.^ORCID,Trinchieri Giorgio^ORCID,Dzutsev Amiran K.^ORCID

Funder

Melanoma Research Foundation

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-01698-2.pdf

Reference81 articles.

1. Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015).

2. Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).